The U.S. Food and Drug Administration (FDA) has cleared BrainSpec Core, a platform that performs non-invasive measurements of brain chemistry, for use in diagnosing some of the most common diseases that affect the brain, including multiple sclerosis (MS).
Developed by BrainSpec, the platform uses magnetic resonance spectroscopy (MRS) to measure the levels of brain metabolites, which are products of metabolism made during cellular activities, and create a “virtual biopsy” of the brain. Read more HERE…